Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 853 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| AMG 853 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AMG 853 | DRUG | AMG 853 5 mg (BID) |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Males or females 18 to 65 years of age * Percent of predicted FEV1 ≥ 50% and ≤ 80% * At least 12% reversibility over pre-bronchodilator FEV1 * Inhaled corticosteroid (ICS) ≥ 200 and ≤ 1000 µg/day fluticasone or equivalent. * Ongoing asthma symptoms with ACQ score ≥ 1.5 points ...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
AMG 853 was studied as a treatment for asthma. It was evaluated in patients whose asthma was not adequately controlled, including a Phase 2 study in adults and a Phase 1 study in adolescents aged 12 years and older. It is an investigational small molecule and is not an approved asthma therapy.
AMG 853 is developed by Amgen Inc., which trades on Nasdaq under the ticker AMGN. Amgen sponsored the clinical program for the drug in asthma, including the Phase 2 study in adults with inadequately controlled disease and the Phase 1 study in adolescents.
AMG 853 reached Phase 2 clinical development for asthma. Two trials have been completed: a Phase 2 study in adults with inadequately controlled asthma and a Phase 1 study in adolescents. No trials are currently active, and the drug is investigational rather than approved.
AMG 853 has been studied in two completed asthma trials. NCT01018550 was a Phase 2 study in 397 adults with inadequately controlled asthma. NCT01137565 was a Phase 1 safety, tolerability, and pharmacodynamics study in 23 adolescents aged 12 years and older with asthma.
Yes. The AMG 853 clinical program used randomized, double-blind, placebo-controlled designs. The two completed asthma trials together enrolled 420 participants. The Phase 2 study in adults enrolled 397 subjects, and the Phase 1 adolescent study enrolled 23 subjects.
AMG 853 is not an approved medicine. It is an investigational small molecule that was studied in Phase 2 for asthma, and both of its completed trials have ended. No active trials are ongoing for AMG 853, and it has not been cleared for marketing.